Nuvectis Pharma annual stock-based compensation
2021
2022
2023
2024
2025
Nuvectis Pharma Stock-Based Compensation Growth & History (NVCT)
Nuvectis Pharma's stock-based compensation was $6.0M for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.0M | $1.2M | +24.17% |
| 2024 | 2024-12-31 | $4.9M | $153,000 | +3.25% |
| 2023 | 2023-12-31 | $4.7M | $3.0M | +175.63% |
| 2022 | 2022-12-31 | $1.7M | −$185,000 | −9.78% |
| 2021 | 2021-12-31 | $1.9M | — | — |
Nuvectis Pharma quarterly stock-based compensation
Q1.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | −$22,000 | −1.27% |
| Q1 2026 | 2026-03-31 | $1.9M | $482,000 | +35.23% |
| Q4 2025 | 2025-12-31 | $1.5M | $335,000 | +29.36% |
| Q3 2025 | 2025-09-30 | $1.5M | $298,000 | +25.71% |
| Q2 2025 | 2025-06-30 | $1.7M | $469,000 | +37.16% |
| Q1 2025 | 2025-03-31 | $1.4M | $72,000 | +5.56% |
| Q4 2024 | 2024-12-31 | $1.1M | −$79,000 | −6.48% |
| Q3 2024 | 2024-09-30 | $1.2M | $26,000 | +2.29% |
| Q2 2024 | 2024-06-30 | $1.3M | $312,000 | +32.84% |
| Q1 2024 | 2024-03-31 | $1.3M | −$106,000 | −7.56% |
| Q4 2023 | 2023-12-31 | $1.2M | $738,000 | +153.11% |
| Q3 2023 | 2023-09-30 | $1.1M | $574,000 | +102.68% |
| Q2 2023 | 2023-06-30 | $950,000 | $440,000 | +86.27% |
| Q1 2023 | 2023-03-31 | $1.4M | $1.2M | +798.72% |
| Q4 2022 | 2022-12-31 | $482,000 | — | — |
| Q3 2022 | 2022-09-30 | $559,000 | $423,000 | +311.03% |
| Q2 2022 | 2022-06-30 | $510,000 | — | — |
| Q1 2022 | 2022-03-31 | $156,000 | $156,000 | — |
| Q3 2021 | 2021-09-30 | $136,000 | — | — |
| Q1 2021 | 2021-03-31 | $0 | — | — |
Nuvectis Pharma stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's stock-based compensation increased from $1.9M to $6.0M, a change of $4.1M. The latest reported quarter, Q2 2026, shows $1.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗